Clinical review: Patency of the circuit in continuous renal replacement therapy - Wikidata - wikimedia - TriplyDB

Clinical review: Patency of the circuit in continuous renal replacement therapy

Clinical review: Patency of the circuit in continuous renal replacement therapy

http://www.wikidata.org/entity/Q33375906

about

Renal replacement therapy in acute kidney injury: controversy and consensus Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference.Decreased platelet count in patients receiving continuous veno-venous hemofiltration: a single-center retrospective study.Platelet Consumption and Filter Clotting Using Two Different Membrane Sizes during Continuous Venovenous Haemodiafiltration in the Intensive Care Unit.Polyethyleneimine-treated polyacrylonitrile membrane hemofilter for critically ill patients receiving anticoagulant-free prolonged intermittent renal replacement therapy: a single-center, prospective, self-controlled pilot study.Continuous renal replacement treatment and the 'bleeding patient'Year in review in Intensive Care Medicine 2010: I. Acute renal failure, outcome, risk assessment and ICU performance, sepsis, neuro intensive care and experimentals Regional citrate anticoagulation for RRTs in critically ill patients with AKI.Early mobilization on continuous renal replacement therapy is safe and may improve filter life.Recurrent white thrombi formation in hemodialysis tubing: a case report.Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?Implementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and trauma intensive care unit: impact on clinical and economic aspects-an observational study.Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials.Discrepant post filter ionized calcium concentrations by common blood gas analyzers in CRRT using regional citrate anticoagulation Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.Chloride content of solutions used for regional citrate anticoagulation might be responsible for blunting correction of metabolic acidosis during continuous veno-venous hemofiltration.Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With Acute Respiratory Distress Syndrome and Acute Kidney Injury: The Pulmonary and Renal Support in Acute Respiratory Distress Syndrome Study.How to deal with dialysis catheters in the ICU setting.Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.Guidewire exchange vs new site placement for temporary dialysis catheter insertion in ICU patients: is there a greater risk of colonization or dysfunction?Year in review 2007: Critical Care--nephrology.Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy.Nursing essential principles: continuous renal replacement therapy.Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Acute kidney injury after pediatric cardiac surgery.Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.A service evaluation comparing CVVH an CVVHD in minimising circuit failure.What is this chocolate milk in my circuit? A cause of acute clotting of a continuous renal replacement circuit: Answers.Hemofiltration induces generation of leukocyte-derived CD31+/CD41- microvesicles in sepsis.Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study.Heparin algorithm for anticoagulation during continuous renal replacement therapy.Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy.Real-time circuit pressures correlate poorly with circuit longevity in anticoagulant-free, predilution continuous venovenous hemofiltration.[Acute renal failure: the fundamental change in a syndrome from simple organ failure to systemic disease process].Complications of regional citrate anticoagulation: accumulation or overload?The role of the specialized team in the operation of continuous renal replacement therapy: a single-center experience.

P2860

Q26998864-CB733C89-FAB2-4F9E-B2B5-61D783CE7FD4 Q30234560-FB7578D9-F250-4994-BF53-0E158FD1847E Q33415284-D5A8C698-CE65-4E2C-8BE5-C6D34E4EC33E Q33415569-C1024C0E-DA58-450D-A388-B084547527F7 Q33443163-557271CB-5908-4109-980A-9903AAA60620 Q34521736-AAA3AEFC-AE5E-40D9-92D7-052F035AFA0B Q34534501-09F249D9-4FED-4D54-8BBF-21CF5015C1B1 Q34629661-EDC76016-6073-44A5-A460-6C61D3839E34 Q34671001-39B59FA0-7735-4FF9-A32A-D872043D509F Q35181038-41D43735-3374-4706-86A2-FFAEAC9C0C99 Q35190273-C0F528A2-0354-4C9C-A33E-6547C07B013D Q35567100-3AA55A0E-0CBD-4613-B6FF-F4E6C01B0AEC Q35902914-5CA4FBA7-A025-4056-9202-FD0961EAB8BA Q36017130-81B1D795-B5A6-41AD-81A6-73ADD2A98EAA Q36041145-B7C2338D-A905-457E-8AF8-9970CC925D10 Q36104484-22AC6208-9BD0-4F2F-AACA-3AD152DF39AB Q36113753-B77EB04A-71A6-42C6-A4F5-0859F30E8B12 Q36285489-63735EAD-D100-477E-99E1-625F92467261 Q36287931-7F763EE8-1668-4D56-8064-9AEE99940EAE Q36478648-94683DFA-98A9-4779-8E00-2E1E02CF0D30 Q36902584-FD4E62E7-710F-44A9-8FFE-6B167D8725D3 Q37119964-A82C4D6A-7E64-44C4-96E7-AF756E32B979 Q37139957-B0853F14-5096-41AC-AFAD-13884A563673 Q37317232-909CD7CA-33FA-42CE-8630-856612EB99C3 Q37582081-5E607D95-AC67-48CF-B0C3-207A7156B7F8 Q38263018-86937D98-0565-4140-806D-1BA8500AC5CE Q38382954-934B0713-6A4A-4083-9949-F5C7E9B444DA Q38799853-B0FB6B8A-58AF-4C73-A60D-090B9D1A9756 Q39936905-8D61AF75-1FA8-4DC3-A698-700D9004457C Q40001887-34E00484-FA29-4641-A7C4-BEC078100AF5 Q40053518-480D8304-7EB9-43E9-9B39-E895A63EEB20 Q41605422-9250EE21-E69D-4F5A-8890-0508A5481652 Q41839496-1F95B5FF-3598-4864-9AA0-D5D2B34AD25B Q41902331-8694A793-8750-4FE4-A77F-B70CA27BC963 Q42848627-6BEA9516-A85A-494C-87EA-8DB396F0F984 Q43536785-6071B046-F6BA-46BE-B540-713D027F9C0B Q44635805-E02CC324-73E2-48DB-AA6D-BD9A9B7BABBB Q46099618-D592F9D4-BE9D-48EE-A1E1-8999AD994518 Q46518144-1ABCAE9B-762E-4D07-A93B-A140ED65EFBB Q47110248-F598ED2C-EB8A-4B3A-BF7D-48F2FB7B05F6

P2860

Clinical review: Patency of the circuit in continuous renal replacement therapy

http://www.wikidata.org/entity/Q33375906

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Clinical review: Patency of the circuit in continuous renal replacement therapy

@ast

Clinical review: Patency of the circuit in continuous renal replacement therapy

@en

type

label

Clinical review: Patency of the circuit in continuous renal replacement therapy

@ast

Clinical review: Patency of the circuit in continuous renal replacement therapy

@en

prefLabel

Clinical review: Patency of the circuit in continuous renal replacement therapy

@ast

Clinical review: Patency of the circuit in continuous renal replacement therapy

@en

P1433

Q33375906-9FE18134-2114-4290-9740-8A95E798F49B

P1476

Q33375906-283E6ADF-61F9-4D74-94E0-ABFD74CF1CC9

P2093

Q33375906-61842D7C-A078-4AB2-9F6A-4CDF486A3BE2

Q33375906-C866BD32-C093-4AA3-AEAB-216B133F5F90

P2860

Q33375906-04EE68F1-67AF-413A-ABF1-EE2EFB479F04

Q33375906-06367459-489E-4103-80EE-496157EDCE35

Q33375906-0FF5C561-E049-49D2-A497-454B9808DAA1

Q33375906-117A648F-FB38-4344-B388-8322200B82E8

Q33375906-117FC2EA-F4FC-4B65-BF46-0FB9B8EEEE86

Q33375906-12B5F07B-8040-4F04-B7BF-099206FFAAB4

Q33375906-157C133B-3A56-4977-8D94-2BA5613BA754

Q33375906-180871D9-95CE-40A5-91A7-3B7E07A0FD64

Q33375906-1A10C9E5-3BAC-40B9-B13C-FF675DD1B9CB

Q33375906-22C3BBE6-B256-4A2A-816F-619B354574F4

P2888

Q33375906-AB9AE9A0-267F-4912-BD94-5034BA73E29F

P304

Q33375906-97EEFDA0-FF2F-41B1-841F-81B3F76044E5

P31

Q33375906-8CE461B1-5E86-4940-BE27-28DBB231DB73

Q33375906-F98929C6-1D79-4B21-A708-1F3907A2BE75

P356

Q33375906-6C01441F-7403-4CAE-ADE6-F4EE35F05499

P433

Q33375906-8940F791-5F72-4CBB-A90E-BF5F23FAD814

P478

Q33375906-300DE7D9-80DC-465F-8B82-F0F2ED5402AE

P577

Q33375906-6BDCA9FD-BAC5-4262-8DA3-CF3B99947C17

P5875

Q33375906-9A293EB6-1ED7-4D16-94D0-A7A4A6F47F3D

P6179

Q33375906-9FC4840B-4C5F-4F51-8B81-E461E95B5826

P698

Q33375906-0D1CDEC3-224E-4312-A3D1-3E36F00F3619

P932

Q33375906-7FB11018-4018-41E9-94DA-49552DA68541

P356

P1433

P1476

Clinical review: Patency of the circuit in continuous renal replacement therapy

@en

P2093

Heleen M Oudemans-van Straaten

http://www.w3.org/2001/XMLSchema#string

Michael Joannidis

http://www.w3.org/2001/XMLSchema#string

P2860

Coagulation abnormalities in critically ill patients

A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.

Frequency of heparin-induced thrombocytopenia in critical care patients.

Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.

Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.

Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin.

Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

P2888

P304

218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC5937

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6204549

http://www.w3.org/2001/XMLSchema#string

P6179

1047660835

http://www.w3.org/2001/XMLSchema#string

P698

17634148

http://www.w3.org/2001/XMLSchema#string

P932

2206533

http://www.w3.org/2001/XMLSchema#string